Inventor · disambiguated record
Darya Burakov
Also filed as: BURAKOV DARYA
26 granted patents·12 pending applications·80 citations·filing 2010–2025
95Inventor score
Top patents by PatentIndex Score
38 records- 0197US9816110B2CHO integration sites and uses thereofREGENERON PHARMA·Filed 2015·Granted Nov 14, 2017·19 cites·29 claims
- 0295US8409838B2Fucosylation-deficient cellsCHEN GANG·Filed 2010·Granted Apr 2, 2013·18 cites·12 claims
- 0394US9193786B2Production cell line enhancersREGENERON PHARMA·Filed 2015·Granted Nov 24, 2015·6 cites·14 claims
- 0493US9228012B2Production cell line enhancersREGENERON PHARMA·Filed 2015·Granted Jan 5, 2016·6 cites·10 claims
- 0591US9079954B2Production cell line enhancersREGENERON PHARMA·Filed 2013·Granted Jul 14, 2015·6 cites·3 claims
- 0690US9732357B2Efficient selectivity of recombinant proteinsREGENERON PHARMA·Filed 2015·Granted Aug 15, 2017·3 cites·41 claims
- 0789US11268109B2CHO integration sites and uses thereofREGENERON PHARMA·Filed 2021·Granted Mar 8, 2022·1 cites·15 claims
- 0889US9550823B2Fucosylation-deficient cellsREGENERON PHARMA·Filed 2015·Granted Jan 24, 2017·2 cites·13 claims
- 0989US9206455B2Fucosylation-deficient cellsREGENERON PHARMA·Filed 2013·Granted Dec 8, 2015·4 cites·12 claims
- 1088US10227401B2Production cell line enhancersREGENERON PHARMA·Filed 2015·Granted Mar 12, 2019·2 cites·21 claims
- 1187US9688751B2Production cell line enhancersREGENERON PHARMA·Filed 2016·Granted Jun 27, 2017·2 cites·38 claims
- 1286US12054751B2Fucosylation-deficient cellsREGENERON PHARMA·Filed 2022·Granted Aug 6, 2024·0 cites·12 claims
- 1385US11530277B2Compositions and methods for making antibodies based on use of an expression-enhancing locusREGENERON PHARMA·Filed 2017·Granted Dec 20, 2022·2 cites·41 claims
- 1485US10457959B2Efficient selectivity of recombinant proteinsREGENERON PHARMA·Filed 2017·Granted Oct 29, 2019·2 cites·33 claims
- 1585US9382315B2Production cell line enhancersREGENERON PHARMA·Filed 2014·Granted Jul 5, 2016·2 cites·20 claims
- 1684US11085053B2Efficient selectivity of recombinant proteinsREGENERON PHARMA·Filed 2019·Granted Aug 10, 2021·1 cites·9 claims
- 1782US10006070B2Fucosylation-deficient cellsREGENERON PHARMA·Filed 2016·Granted Jun 26, 2018·1 cites·20 claims
- 1882US9758592B2Recombinant cell surface capture proteinsREGENERON PHARMA·Filed 2013·Granted Sep 12, 2017·3 cites·8 claims
- 1979US11560550B2Fucosylation-deficient cellsREGENERON PHARMA·Filed 2021·Granted Jan 24, 2023·0 cites·12 claims
- 2077US10611831B2Production cell line enhancersREGENERON PHARMA·Filed 2019·Granted Apr 7, 2020·0 cites·40 claims
- 2176US12503520B2Compositions and methods for making antibodies based on use of an expression-enhancing locusREGENERON PHARMA·Filed 2022·Granted Dec 23, 2025·0 cites·20 claims
- 2276US11788102B2CHO integration sites and uses thereofREGENERON PHARMA·Filed 2019·Granted Oct 17, 2023·0 cites·22 claims
- 2375US12234472B2Eukaryotic cells comprising adenovirus-associated virus polynucleotidesREGENERON PHARMA·Filed 2022·Granted Feb 25, 2025·0 cites·15 claims
- 2474USRE48651EProduction cell line enhancersREGENERON PHARMA·Filed 2019·Granted Jul 20, 2021·0 cites·38 claims
- 2574US2021340564A1Efficient selectivity of recombinant proteinsREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 2672US2020080124A1Fucosylation-deficient cellsREGENERON PHARMA·Filed 2019·Application pending·0 cites
- 2771US2019024129A1Fucosylation-deficient cellsREGENERON PHARMA·Filed 2018·Application pending·0 cites
- 2868US10351622B2Production cell line enhancersREGENERON PHARMA·Filed 2017·Granted Jul 16, 2019·0 cites·35 claims
- 2967US2018030480A1Novel cho integration sites and uses thereofREGENERON PHARMA·Filed 2017·Application pending·0 cites
- 3065US2023287460A1Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sitesREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3165US2023304062A1Controlled transcription of polynucleotidesREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3260US11512144B2Compositions and methods for making antibodies based on use of an expression-enhancing lociREGENERON PHARMA·Filed 2017·Granted Nov 29, 2022·0 cites·43 claims
- 3359US2025154524A1Eukaryotic cells comprising adenovirus-associated virus polynucleotidesREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 3457US2018118852A1Recombinant Cell Surface Capture ProteinsREGENERON PHARMA·Filed 2017·Application pending·0 cites
- 3554US2014072979A1Isolating cells expressing secreted proteinsREGENERON PHARMA·Filed 2013·Application pending·0 cites
- 3650US2017241887A1Isolating Cells Expressing Secreted ProteinsREGENERON PHARMA·Filed 2017·Application pending·0 cites
- 3746US2014072980A1Isolating cells expressing secreted proteinsREGENERON PHARMA·Filed 2013·Application pending·0 cites
- 3841US2016251411A1Host cell protein modificationREGENERON PHARMA·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Darya Burakov files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →